

**RYVERNA**

**(Crizanlizumab)**

**100 mg/ 10 ml Concentrate for solution for infusion**

Patient Information Leaflet

Document status: Final

Approval date: 28 January 2022

**SCHEDULING STATUS: S4**

**RYVERNA 100 mg/ 10 ml Concentrate for solution for infusion**

crizanlizumab

Contains sugar: sucrose (753.3 mg per 10ml vial).

**Read all of this leaflet carefully before you are given RYVERNA**

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or pharmacist, nurse or other health care provider.
- RYVERNA has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

**What is in this leaflet**

1. What RYVERNA is and what it is used for
2. What you need to know before you are given RYVERNA
3. How RYVERNA is given
4. Possible side effects
5. How to store RYVERNA
6. Contents of the pack and other information

## **1. What RYVERNA is and what it is used for**

### **What RYVERNA is**

RYVERNA contains the active substance crizanlizumab, which belongs to a group of medicines called monoclonal antibodies.

### **What RYVERNA is used for**

RYVERNA is used to prevent painful episodes (crises) of sickle cell disease in patients aged 16 years and over.

Sickle cell disease is an inherited blood disorder. It causes affected red blood cells to become sickle-shaped and have difficulty passing through small blood vessels. Additionally, in sickle cell disease the blood vessels are damaged and sticky due to the ongoing chronic inflammation. This leads to blood cells sticking to the blood vessels, causing acute episodes of pain and organ damage.

### **How RYVERNA works**

Patients with sickle cell disease have higher levels of a protein called P-selectin. This makes both the blood vessels and certain blood cells sticky. RYVERNA binds P-selectin. This should stop blood cells sticking to the vessel walls and help prevent painful episodes (crises).

If you have any questions about how RYVERNA works or why this medicine has been prescribed for you, ask your doctor, pharmacist, or healthcare provider.

## **2. What you need to know before you are given RYVERNA**

RYVERNA is administered into a vein (intravenously) as an infusion. RYVERNA can cause unwanted reactions (side effects) when infused into your body.

Your doctor or healthcare provider will monitor you for signs and symptoms of infusion reactions.

### **Warnings and precautions**

Talk to your doctor before you are given RYVERNA if the following applies to you:

If you need to have any blood tests, tell the doctor or healthcare provider that you are on treatment with RYVERNA. This is important because RYVERNA may interfere with a laboratory test to measure the number of platelets in your blood.

If this applies to you, your doctor will decide whether you should be given RYVERNA.

**Tell your doctor immediately** if you get any of the following symptoms during or within 24 hours after you have been given RYVERNA:

- Fever,
- Chills,
- Shivering,
- Nausea,
- Vomiting,
- Diarrhoea,
- Tiredness,
- Dizziness,
- Pain where the infusion needle is inserted,
- Pain in various locations,
- Headache
- Blisters,
- Itching (Hives),

- Shortness of breath or wheezing.

Some of these symptoms, may be signs of an infusion-related reaction:

If you experience an infusion-related reaction, the RYVERNA infusion may need to be stopped or slowed down. You may be given additional medicines to treat the symptoms of your infusion-related reaction. Your next RYVERNA infusions may continue to be given more slowly and/or with medicines to reduce the risk of an infusion-related reaction.

### **Children and adolescents**

RYVERNA should not be used in children or adolescents below 16 years of age.

### **Other medicines and RYVERNA**

Tell your doctor if you are using, have recently used or might use any other medicines.

### **Pregnancy and breastfeeding**

There is limited information about the safety of RYVERNA in pregnant women.

It is not known whether RYVERNA or the ingredients of RYVERNA can pass into breast milk.

If you are pregnant or breastfeeding, think you might be pregnant or are planning to have a baby, ask your healthcare provider for advice before receiving this medicine.

Your doctor will discuss with you the potential risk(s) of RYVERNA during pregnancy or breastfeeding.

RYVERNA contains sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product

### **Driving and using machines**

Treatment with RYVERNA may lead to dizziness or spinning sensation. You should therefore be cautious when driving or using machines during your treatment with RYVERNA.

### **3. How RYVERNA is used**

You will be given RYVERNA by a doctor or healthcare provider.

If you have any questions about how RYVERNA is given, ask the doctor or healthcare provider who is giving you the infusion.

Your doctor or healthcare provider will tell you when you will have your infusions and follow-up appointments.

### **How much and how often RYVERNA is given**

The recommended dose is 5 mg per kilogram of body weight. You will be given the first infusion at Week 0 and the second infusion two weeks later (Week 2). After that you will be given an infusion every 4 weeks thereafter.

### **Method of administration**

RYVERNA is administered into a vein (intravenously) as an infusion over a period of 30 minutes.

RYVERNA can be given alone or with other treatments such as hydroxyurea (hydroxycarbamide).

### **How long does RYVERNA treatment last for**

This is a long-term treatment, possibly lasting for months or years. You should discuss with your doctor or healthcare provider how long you will need to receive treatment. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.

### **If you forget a scheduled RYVERNA infusion**

It is very important to receive all your infusions. If you miss an appointment for an infusion, contact your doctor or healthcare provider as soon as possible to reschedule.

### **If you stop RYVERNA treatment**

Do not stop RYVERNA treatment unless your doctor or healthcare professional tells you that you can.

If you have any further questions on the use of this medicine, ask your doctor or healthcare provider.

## **4. Possible side effects**

This medicine can cause side effects, not all side effects reported for RYVERNA are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking RYVERNA, please consult your health care provider for advice.

### **Some side effects could be serious**

If you experience any serious side effects during or within 24 hours of the infusion, tell your doctor immediately.

- Fever,
- Chills,
- Shivering,
- Nausea,
- Vomiting,
- Diarrhoea,
- Tiredness,

- Dizziness,
- Pain where the infusion needle is inserted,
- Pain in various locations,
- Headache,
- Blisters,
- Itching (Hives),
- Sweating,
- Shortness of breath or wheezing.

These symptoms can be signs of infusion- related reaction, which is a common side effect (this means it may affect up to 1 in every 10 people).

Other side effects which may occur following RYVERNA treatment include the following listed below. If these side effects become severe, please tell your doctor.

#### Frequent

- Nausea
- Back pain
- Pain in the joints (sign of arthralgia)
- Fever
- Sore throat (oropharyngeal pain)
- Abdominal pain
- Diarrhoea

- Vomiting
- Itching
- Pain in the muscles or bones of the chest (signs of musculoskeletal chest pain)
- Muscle pain (sign of myalgia)
- Redness or swelling and pain at the site of the infusion

Less frequent

- Any pain occurring during or within 24 hours of the infusion, which may be a sign of an infusion-related reaction.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

**Reporting of side effects**

If you get side effects, talk to your doctor. You can also report side effects to SAHPRA via the “6.04 Adverse Drug Reaction Reporting Form”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>. By reporting side effects, you can help provide more information on the safety of RYVERNA.

**5. How to store RYVERNA**

Keep this medicine out of the sight and reach of children.

Store in a refrigerator between 2 °C – 8 °C.

Do not freeze.

Keep the vial in the outer carton to protect from light.

The diluted solution for infusion should be administered as soon as possible.

If not administered immediately, store the prepared solution either:

- At room temperature up to 25°C for no more than 4.5 hours from the start of the preparation to completion of the infusion.
- Under refrigeration at 2°C to 8°C for no more than 24 hours from the time of the preparation to completion of the infusion. This includes the storage of the diluted solution at 2°C to 8°C and the time to warm up at room temperature.

Do not use this medicine after the expiry date, which is stated on the carton.

## **6. Contents of the pack and other information**

### **What RYVERNA contains**

The active substance of RYVERNA is crizanlizumab.

The other ingredients of RYVERNA are sucrose, sodium citrate, citric acid, polysorbate 80 and water for injection.

### **What RYVERNA looks like and contents of the pack**

RYVERNA is supplied as a concentrate for solution for infusion in a single-use vial in packs containing one 10 mL vial.

Each 10 mL vial contains 100 mg of crizanlizumab.

The concentrate for solution for infusion is colorless to slightly brownish-yellow liquid, free from visible particulate matter.

Any unused product or waste material should be disposed of in accordance with local requirements.

**Holder of certificate of registration**

Novartis South Africa (Pty) Ltd.

Magwa Crescent West

Waterfall City,

Jukskei View

Johannesburg 2090

**This leaflet was last revised in**

28 January 2022

**Registration number**

54/30.1/0738

2020-PSB/GLC-1160-s